Schizophrenia and Psychoses

Featured Article

Old Challenges and New Directions in Managing Tardive Dyskinesia

Old Challenges and New Directions in Managing Tardive Dyskinesia

"Since the current generation of psychiatrists has been raised on second-generation antipsychotics and has relatively little experience with first-generation antipsychotics, keeping tardive dyskinesia in mind is not, on the whole, part of their experience or training," said Christoph U. Correll, MD.

Latest

First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide

First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide

Researchers found a suicide attempt rate of 12.0% in first-episode, drug-naive inpatients.

Second Generation Long-Acting Injectable Drugs Effective for Schizophrenia

Second Generation Long-Acting Injectable Drugs Effective for Schizophrenia

The findings support second generation long-acting injectable antipsychotic drug use as early treatment option to increase treatment adherence and to decrease the risk of relapse, hospitalization, and deteriorating social functions.

Potential Utility of Adjunctive Withania somnifera in Schizophrenia Treatment

Potential Utility of Adjunctive Withania somnifera in Schizophrenia Treatment

WSE treatment may be useful in addressing symptom exacerbation in schizophrenia and schizoaffective disorder.

Social Functioning, Treatment With Antipsychotic Agents Associated With Employment in Schizophrenia

Social Functioning, Treatment With Antipsychotic Agents Associated With Employment in Schizophrenia

Investigators examined factors that may improve employment in patients with schizophrenia.

Once-Monthly Perseris Approved for the Treatment of Schizophrenia

Once-Monthly Perseris Approved for the Treatment of Schizophrenia

Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.

Antipsychotic Medication May Affect HDL-Cholesterol Levels for Some Patients With Schizophrenia

Antipsychotic Medication May Affect HDL-Cholesterol Levels for Some Patients With Schizophrenia

These results may be helpful for clinicians when considering the effects of antipsychotic intervention on patient high-density lipoprotein cholesterol levels.

Adolescent Inhalant Use Associated With Higher Risk for Psychosis

Adolescent Inhalant Use Associated With Higher Risk for Psychosis

Inhalant and other substance use during adolescence are increasingly associated with many adverse health and psychosocial outcomes.

Early Interventions Effective in Reducing Psychosis Duration in Military Personnel

Early Interventions Effective in Reducing Psychosis Duration in Military Personnel

These data have implications for the efficacy of the US military healthcare system as a whole in treating psychosis in service members.

Long-Acting Injectables Effective in Patients With Comorbid Psychosis, Substance Use Disorder

Long-Acting Injectables Effective in Patients With Comorbid Psychosis, Substance Use Disorder

As psychosis and substance use disorder comorbidity can make oral medication adherence difficult, long-acting injectable agents may be an effective therapeutic alternative in patients in this demographic.

Classification Models for Diagnosing Schizophrenia With MRI Neuroimaging

Classification Models for Diagnosing Schizophrenia With MRI Neuroimaging

Each of the studied brain modalities could be classified as "gray matter abnormalities" or "white matter disruptions" and may be significant in the pathology of schizophrenia.

Sign Up for Free e-newsletters